CardioExchange Archive

November 3rd, 2014

Selections from Richard Lehman’s Literature Review: November 3rd

Richard Lehman, BM, BCh, MRCGP

This week’s topics include dual-antiplatelet treatment beyond one year after DES implantation, reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome, and more.

---

September 16th, 2013

Selections from Richard Lehman’s Literature Review: September 16th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the AMPLIFY trial, D2B time and mortality among those undergoing primary PCI, and more.

---

September 1st, 2013

Pretreatment with Prasugrel Not Indicated in NSTEMI

Larry Husten, PHD

Pretreatment prasugrel for NSTEMI was not effective in the ACCOAST trial.

---

September 1st, 2013

Inside the ACCOAST Trial of Pretreatment Prasugrel

Gilles Montalescot, MD, PhD, John Ryan, MD, Richard A. Lange, MD, MBA and L. David Hillis, MD

Gilles Montalescot, lead investigator of the ACCOAST trial, discusses why prasugrel pretreatment did not benefit patients with non–ST-segment elevation acute coronary syndromes.

---

November 4th, 2012

Platelet-Function Testing in Coronary Stenting: Frozen in Its Tracks

Gilles Montalescot, MD, PhD

An ARCTIC trial investigator discusses possible reasons why antiplatelet-drug and dosing adjustments, guided by platelet-function testing, did not improve clinical outcomes for stented patients.

---

October 8th, 2012

Selections from Richard Lehman’s Literature Review: October 8th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include beta-blockers and the lack of a cardioprotective effect for certain patients; intra-aortic balloon support for MI with cardiogenic shock; prasugrel vs. clopidogrel for acute coronary syndromes without revascularization; CRP, fibrinogen, and CVD prediction; and a comparison of thrombectomy devices for acute ischemic stroke.

---

September 4th, 2012

Danish Survey Finds Clopidogrel Less Effective in Diabetics

Larry Husten, PHD

A large nationwide survey of MI survivors in Denmark provides new information about the efficacy of antiplatelet therapy with clopdiogrel in patients with diabetes. In a paper published in JAMA, Charlotte Andersson reports on 58,851 MI patients, 12% of whom had diabetes and 60% of whom received clopidogrel. As expected, diabetics had a worse outcome than nondiabetics: the composite […]

---

August 26th, 2012

Prasugrel vs. Clopidogrel in ACS: The TRILOGY Take

John Ryan, MD

TRILOGY author Matt Roe answers CardioExchange’s questions about his team’s study of clopidogrel vs. prasugrel in ACS.

---

August 26th, 2012

TRILOGY at ESC: No Advantage for Prasugrel Over Clopidogrel in Medical ACS Patients

Larry Husten, PHD

The newer antiplatelet agent prasugrel was no better than the old standby clopidogrel for treating patients with acute coronary syndrome (ACS) who are not undergoing revascularization. The results of the TRILOGY ACS (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) trial were presented by Matt Roe at the European Society of […]

---

July 16th, 2012

Ticagrelor Joins Clopidogrel and Prasugrel in Updated NSTEMI Guidelines

Larry Husten, PHD

Ticagrelor (Brilinta, AstraZeneca) gains equal standing with prasugrel (Effient, Lilly) and clopdiogrel in the newly released focused update of the ACCF/AHA guidelines for unstable angina and non-ST-elevation myocardial infarction (NSTEMI). The change had been widely anticipated since last year’s FDA approval of ticagrelor. “We have put it on equal footing with two other antiplatelet medications, clopidogrel […]

---